BioXcel Therapeutics Inc (BTAI) ticks all the boxes for top investors with its surprise performance of -27.24% last month.

On Monday, BioXcel Therapeutics Inc (NASDAQ: BTAI) opened lower -7.58% from the last session, before settling in for the closing price of $2.11. Price fluctuations for BTAI have ranged from $1.91 to $34.00 over the past 52 weeks.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Company’s average yearly earnings per share was noted -3.65% at the time writing. With a float of $20.68 million, this company’s outstanding shares have now reached $28.15 million.

BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioXcel Therapeutics Inc is 30.90%, while institutional ownership is 34.78%. The most recent insider transaction that took place on Jun 16, was worth 605,501. In this transaction CEO and President of this company sold 30,000 shares at a rate of $20.18, taking the stock ownership to the 39,903 shares. Before that another transaction happened on Jun 15, when Company’s CEO and President sold 30,000 for $21.54, making the entire transaction worth $646,226. This insider now owns 39,903 shares in total.

BioXcel Therapeutics Inc (BTAI) Latest Financial update

If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$1.72 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$1.3) by -$0.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -3.65% per share during the next fiscal year.

BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators

Check out the current performance indicators for BioXcel Therapeutics Inc (BTAI). In the past quarter, the stock posted a quick ratio of 2.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.07.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.36, a number that is poised to hit -0.92 in the next quarter and is forecasted to reach -2.37 in one year’s time.

Technical Analysis of BioXcel Therapeutics Inc (BTAI)

Let’s dig in a bit further. During the last 5-days, its volume was 5.05 million. That was better than the volume of 1.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.54%. Additionally, its Average True Range was 0.41.

During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 1.08%, which indicates a significant decrease from 1.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 270.74% in the past 14 days, which was higher than the 142.15% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.08, while its 200-day Moving Average is $8.30. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $2.29. Second resistance stands at $2.63. The third major resistance level sits at $2.81. If the price goes on to break the first support level at $1.77, it is likely to go to the next support level at $1.59. The third support level lies at $1.26 if the price breaches the second support level.

BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats

There are currently 29,930K shares outstanding in the company with a market cap of 58.36 million. Presently, the company’s annual sales total 380 K according to its annual income of -165,760 K. Last quarter, the company’s sales amounted to 340 K and its income totaled -50,490 K.